Patent Docs
This blawg "focuses on recent developments in biotechnology and pharmaceutical patent law. This weblog offers updates regarding changes in patent office rules and procedures that affect biotech/pharma patent prosecution, provides summaries of recent court decisions that impact biotech/pharma patent litigation and prosecution, and monitors newly filed biotech/pharma patent litigation."
Author: Donald Zuhn and Kevin Noonan are partners at McDonnell Boehnen Hulbert & Berghoff in Chicago; Chris Singer and Sherri Oslick are associates at the firm. Jason Derry is an in-house patent attorney.
Blawg Related Categories: Intellectual Property Law • Patent Law • Science & Technology Law • Associate • In-house Lawyer • Partner
Recent Posts from Patent Docs
-
Bilski CLE Options
On Monday, November 9, 2009, the Supreme Court will hear oral argument in In re Bilski, and two CLE providers plan to offer same day or next day coverage of the proceedings. Practising Law Institute…
-
CLE on Avoiding Inequitable Conduct Claims
Managing IP and Lexis Nexis will be offering a free web seminar entitled: "Avoid Patent Unenforceability Claims Due to Inequitable Conduct" on November 12, 2009 from 12:00-1:30 PM (EST). J. Timothy Meigs of BD Technologies,…
-
Follow-on Biologics News Briefs - No. 9
By Donald Zuhn -- Patient Groups Back Senate and House Committee FOB Legislation In September, twenty-seven patients' groups sent a letter to Sen. Harry Reid (D-NV), Sen. Mitch McConnell (R-KY), Speaker of the House Nancy…
-
Biotech/Pharma Docket
By Suresh Pillai -- Mayo Seeks Supreme Court Review in Prometheus Labs Case Following the U.S. Court of Appeals for the Federal Circuit's ruling that Prometheus Laboratories' method patents were valid under In re Bilski,…
-
House Health Care Bill Includes Biosimilar Licensure Pathway
By Donald Zuhn -- Last Thursday, Rep. John Dingell (D-MI) introduced the Affordable Health Care for America Act (H.R. 3962) in the House of Representatives. The 1,990-page bill, which was co-sponsored by Rep. Robert Andrews…
-
12 Senators Write in Support of 12-Year Data Exclusivity Period
By Donald Zuhn -- On October 23, twelve Senators sent a letter to Sen. Harry Reid (D-NV), asking the Senate majority leader to "support the establishment of a responsible pathway for the approval of follow-on…
-
BRCA Patent Suit to Continue in Southern District of New York
By Kevin E. Noonan -- Judge Robert W. Sweet of the Southern District of New York ruled against the defendants' motions to dismiss in Association for Molecular Pathology v. U.S. Patent and Trademark Office (see…
-
Follow-on Biologics Data Exclusivity Debate Scorecard - Part III
By Donald Zuhn -- Over the past twelve months, Patent Docs has reported on a number of papers, letters, and statements that outline positions taken by various players in the follow-on biologics (FOB) data exclusivity…
-
Modeling a Zombie Infection Outbreak
By Andrew Williams -- As many children and partygoers prepare to dress up as the undead for trick-or-treating fun or Halloween-themed parties, the scientific community is taking the potential of a Zombie attack more seriously.…
-
Follow-on Biologics Data Exclusivity Debate Scorecard - Part II
By Donald Zuhn -- Over the past twelve months, Patent Docs has reported on a number of papers, letters, and statements that outline positions taken by various players in the follow-on biologics data exclusivity debate.…